diabetes

William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

By Jill Clendening
June 22, 2022

Gannon selected for American Diabetes Association Award

Maureen Gannon, PhD, professor of Medicine, Molecular Physiology and Biophysics, and Cell and Developmental Biology, is the recipient of the 2022 Lois Jovanovic Transformative Woman in Diabetes Award presented by the American Diabetes Association (ADA).

By Jill Clendening
May 24, 2022

Diabetes, cardiovascular drug targets

Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

By Leigh MacMillan
From left, Raymond C. Harris, MD, Shirong Cao, MD, PhD, Ming-Zhi Zhang, MD, MSc, and colleagues are studying the role of inflammation in obesity.
May 12, 2022

Study sheds light on the dark side of obesity

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

By Bill Snyder
May 5, 2022

Gene network linked to Type 2 diabetes

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

By Joshua Baker
January 13, 2022

Eighteen years ago Kanisha Sizemore got a new kidney and pancreas. With her job in the Transplant Pharmacy she gives patients hope and perspective.

“Being a transplant recipient is a blessing, but it is also life changing in several ways.”

By Matt Batcheldor
November 11, 2021

New way to bEET insulin resistance

Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
By Bill Snyder
August 27, 2021

Study proves standardized protocol can support reliable MRI use for multisite pancreatic research

Researchers with the Vanderbilt Diabetes Research and Training Center (DRTC) at Vanderbilt University Medical Center led a multisite study which has demonstrated that, when controlled and standardized, quantitative magnetic resonance imaging (MRI) of the pancreas is highly reproducible when using different MRI hardware and software at different geographic locations.
By Jill Clendening
August 5, 2021

Gene expression in diabetic nephropathy

Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.
By Shivani Sharma
July 15, 2021

Study shows continuous glucose monitors improve management of type 2 diabetes

For patients with type 2 diabetes treated with basal or long-acting insulin, the use of continuous glucose monitors (CGMs) can result in significantly lower hemoglobin A1C (a blood test that reflects average blood glucose levels over three months), and better management of the disease according to a study recently published in the journal JAMA.
By Jill Clendening
May 20, 2021

Beta cell regeneration

Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes.
By Leigh MacMillan
March 18, 2021

HIV, diabetes and immune cells in fat

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.
By Leigh MacMillan
March 4, 2021

Targeting glucagon action in diabetes

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.
By Leigh MacMillan
1 2 3 4 5 … 14